Clinical Trial Update: Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial examining the ease of use of the Lebrikizumab auto-injector pen in participants with atopic dermatitis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-07-29